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Abstract
Background: The prevalence of type 2 diabetes (T2D) is growing globally and hospital-based outpatient clinics are
burdened with increasing numbers of patients. To ensure high quality treatment and care, it is necessary to
structurally reorganise the management of patients with T2D. The objective of this study is to test if T2D patients
(who are at intermediate risk of or are already having incipient diabetic complications) jointly managed by a
hospital-based outpatient clinic and general practitioners (shared care programme) have a non-inferior outcome
compared to an established programme in a specialised (hospital based) outpatient diabetes clinic.
Methods: The study is designed as a randomised controlled trial. The shared care model will be tested during a
period of 3 years, with data collection at baseline and at 12, 24 and 36 months. All patients will be offered four
medical visits a year; the shared care intervention consists of one annual comprehensive check-up at the outpatient
clinic and three quarterly visits at the general practitioners’ office. The control group will be followed with four
quarterly visits at the outpatient clinic, including an annual comprehensive check-up. In the outpatient clinic, the
patients will be treated by a specialised diabetes team, including an endocrinologist. On the basis of a predefined
stratification model, we will recruit patients stratified to be at intermediate risk of or already having incipient
diabetic complications. We plan to include 140 patients. The primary outcome is glycated haemoglobin. Other
outcome measures include (1) the proportion of patients who meet the Danish standard indicators reflecting
quality of care; (2) quality of life measured by Short Form 36; and (3) the functionality of the patients’ families
measured by Family Assessment Measure III. The experiences of the patients and families when participating in the
shared care program will be explored by collecting dyadic interviews.
Discussion: This study will evaluate the quality of a shared care programme for patients with T2D, and provide
evidence about advantages and disadvantages compared with a programme in a specialised outpatient clinic. The
results may provide important information on how to organise the care for patients with T2D in the future.
Trial Registration: This trial was registered with Clinicaltrials.gov on 21 October 2015, registration number:
NCT02586545.
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Background
The incidence and prevalence of type 2 diabetes (T2D)
are increasing globally [1–3]. T2D is a multifactorial and
chronic disease associated with serious complications
and co-morbidities, and it is among the 10 leading
causes of death worldwide [4, 5]. The number of adults
with diabetes is estimated to rise by 55 % during a 22-
year period, from 382 million individuals in 2013 to 592
million individuals in 2035 [2, 3]. Compared to the gen-
eral population, patients with T2D have increased mor-
bidity and mortality [6–8] due to an increased risk of
microvascular complications and macrovascular disease
[4]. Living with diabetes is also associated with major
psychosocial implications and impaired quality of life [9,
10]. Furthermore, the disease causes considerable socio-
economic expenditures and healthcare costs, especially
with emerging and manifest complications to the disease
[3, 11, 12]. In order to prevent or delay diabetic compli-
cations, it is essential to stabilise and treat hypergly-
caemia, elevated blood pressure and dyslipidaemia [13–
15]. The treatment targets for these indicators are de-
fined in evidence-based guidelines, but treatment goals
are too often not achieved [16, 17]. The increasing
prevalence of T2D also challenges the healthcare sys-
tems in terms of how to prioritise the limited resources.
Therefore, the need for considering alternative organisa-
tional models for the management of T2D, ensuring
high quality care, is urgent.
During the last decades, numerous models of diabetes
management have been evaluated; among these are
shared care models [18, 19]. Shared care can be defined
as a joint delivery of care conducted in cooperation be-
tween general practitioners (GP) and medical specialists
[20]. In most shared care models, the GP is guided in
the management of T2D on the individual patient level
by the specialised team [21–24]. Thus, the patient may
benefit from the broad knowledge of the GP and the ex-
pertise of the medical specialists. Furthermore, there
may be economic savings for the community as visits at
hospital-based outpatient clinics, in general, are more
expensive than GP visits. The challenges of shared care
may be the difficulty in keeping track of the patients’ vis-
iting schedule in the transition from one healthcare sec-
tor to another and potential loss of information across
the interface of the primary and secondary healthcare
sectors. Moreover, there is a risk of dilution of responsi-
bility for the individual patient among the different
healthcare professionals, potentially leading to ineffective
decision-making and care. According to a previous
Cochrane review, insufficient favourable evidence was
found to support shared care programmes for patients
with chronic diseases [20]. This conclusion, however, is
limited by the interventions being complex and multifa-
ceted as well as the methodological shortcomings and
inadequate length of follow-up of the studies included in
the review. Furthermore, the review did not test shared
care programmes specifically for patients with T2D, but
for chronic diseases in general.
An Australian observational study tested a
community-based T2D management programme run by
specially trained, primary care physicians, who were sup-
ported by an on-site endocrinologist [23]. They found a
significant decrease in glycated haemoglobin (HbA1c)
among patients in the intervention group at 12-months’
follow-up, but no change among patients in the control
group. The latter consisted of patients in long-term
follow-up at the outpatient clinic. However, this result
may be biased because of lack of randomisation, as the
intervention was not offered to all patients, but only to
those who were referred by their GP to the outpatient
clinic during the study period. Furthermore, the patients
in the intervention group had significantly higher HbA1c
than the control group at baseline, but at 12-months
follow-up the HbA1c was similar in the two groups. In
an Irish trial [24], general practice clinics were rando-
mised to conduct either usual care or shared care to pa-
tients with T2D. Shared care consisted of educational
programmes for healthcare professionals in the general
practices, as well as an annual diabetes review performed
in a specialised outpatient clinic. They found no signifi-
cant differences in HbA1c at 18-months follow-up.
Future studies testing the effectiveness of shared care
interventions are recommended to be developed within
research settings and also with high-quality design, well-
defined interventions, and with an extended length of
follow-up period [20]. According to Danish regional
guidelines, patients with T2D in intermediate risk for
progress of diabetic complications, identified via a risk
stratification model, are recommended to be followed in
tight collaboration between GP and specialised and
hospital-based outpatient clinics [25]. In line with these
recommendations, we plan a randomised controlled trial
to test a shared care model in a well-defined group of
patients with T2D, with well-defined transition and deci-
sion making across the healthcare sectors.
Methods/Design
Study design
The present trial is a proof-of-concept study. We aim to
test the effect of a new model of organisation and man-
agement of diabetes care, and compare it with a standar-
dised care management programme in a specialised
outpatient clinic. The study is designed as a randomised
controlled trial testing for non-inferiority between the
two programmes. We hypothesise that patients with
T2D followed in a shared care programme (intervention)
will have a comparable primary outcome (HbA1c) com-
pared to patients receiving standard care (control). The
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study flow is indicated in Fig. 1. The study follows the
guidelines of Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) (Additional file
1).
The settings
The study is a cross-sectional study with several settings.
The intervention takes place in the diabetes outpatient
clinic at Gentofte Hospital, University of Copenhagen,
Hellerup, Denmark, as well as in a number of general
practices in the Capital Region of Denmark. The control
group is managed solely in the outpatient clinic at Gen-
tofte Hospital placed in northern Copenhagen,
Denmark. Gentofte Hospital covers four municipalities
with a total population of approximately 224,000 inhabi-
tants, and with approximately 10,000 inhabitants diag-
nosed with diabetes [22, 23]. There are 106 general
practices located in the four municipalities with a total
of 150 GPs. The hospital-based outpatient clinic is
staffed by a diabetes team consisting of endocrinologists
with special interest in diabetes, diabetes nurses, a diet-
ician, podiatrists, and trained nurses who perform fun-
dus photography, which are evaluated by
ophthalmologists. Currently, the diabetes team is re-
sponsible for the care of approximately 1200 patients
with T2D.
Participants
We will recruit eligible patients followed for T2D by ei-
ther their GP or at the outpatient clinic. A patient is
only eligible if their GP accepts participation in the
study. Therefore, we will recruit GPs before recruiting
study participants. Invitations to participate will be dis-
tributed by mail to all regional GPs referring patients to
Gentofte Hospital. We intend to include approximately
25 GPs, aiming at recruiting six patients from each prac-
tice or until we have reached the predefined number of
patients in the study (n = 140). An endocrinologist and
the primary investigator will make appointments for vis-
iting GPs who have accepted to participate. The duration
of the individual visit at the GP’s office will be of ap-
proximately 2 hours. During the visit, we will identify
patients who are eligible to participate according to the
inclusion criteria. Patients managed by the GP and pa-
tients previously referred from the individual GP to be
managed at the outpatient clinic are identified. Thus,
both patients who have their T2D managed solely by
their GP, or at the outpatient clinic, will be recruited.
Eligible patients will be contacted by phone and, if the
patient shows interest in participating in the study, writ-
ten information will be sent by regular mail or e-mail. If
the patient agrees to participate in the study by giving
written consent, she/he will be invited to a baseline-
screening visit in the outpatient clinic (Fig. 2). If all
Fig. 1 Study flow diagram. The planned flow of participants through the different stages of the study
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inclusion criteria are fulfilled and none of the exclusion
criteria are met, patients will then be randomised to one
of the two groups. Patients who decline to participate or
do not meet the inclusion criteria will continue their
usual T2D care either at the GP or at the outpatient
clinic.
Inclusion criteria
Patients with T2D over the age of 18 years, able to
understand, speak and write Danish, willing to give oral
and written consent, and at predefined risk stratification
level 2, are eligible for the study. According to the risk
stratification model applied (Table 1), patients with T2D
can be stratified into three levels: level 1 (uncompli-
cated), level 2 (intermediate risk) or level 3 (high risk).
The model is an organisational tool intended to graduate
the medical care and treatment according to the severity
and complexity of T2D. Patients stratified at level 1 have
well-controlled T2D and are recommended to be
followed in general practice, whereas patients at level 3
are recommended to be followed in hospital-based out-
patient clinics, as they have dysregulated T2D and/or in-
creasing severity of complications and/or co-morbidity.
Patients stratified at level 2 are moderately dysregu-
lated T2D and/or having incipient complications.
These patients are recommended to be followed in
closer collaboration between hospital and general
practice. The model was originally defined in a report
from the Capital Region of Denmark compiled by dia-
betes specialists, other experts and GPs [26] and
based on current evidence on treatment goals and
cut-off points in diabetes management [27–30]. In the
present trial, the model is slightly modified to make
the model more operational. In a recent study of the
population in our outpatient clinic, we found that
54 % of the patients were stratified to level 2, while
less than 5 % were stratified to level 1 [31].
Exclusion criteria
Patients are excluded if they have other types of diabetes
than T2D, are at risk stratification level 1 or 3 (Table 1),
are pregnant or breastfeeding, have severe co-morbidity
with a life expectancy less than 5 years, or are under
such conditions that they will not be able to attend or
complete the appointments (e.g. due to dementia or psy-
chiatric conditions). Furthermore, we will exclude
Fig. 2 Content of the annual comprehensive check-up in the outpatient clinic
Table 1 Risk stratification model for patients with type 2 diabetes
Level 1 Level 2 Level 3




Metabolic complications No Severe insulin resistancea Very fluctuating plasma glucoseb or severe
hypoglycaemia
CVDd No One previous MACE >1 MACE, symptomatic CVD or NYHA II-IV
Diabetic foot disease No Peripheral neuropathyc or artery
diseased
Previous or existing ulcer or Charcot foot
Retinopathy No or simplex
retinopathy
Progression of retinopathy Macula oedema or proliferative retinopathy
Nephropathy No Micro-albuminuriae Macro-albuminuriaf
All parameters in level 1 have to be fulfilled to be allocated to risk stratification level 1. At risk stratification level 2, at least one parameter has to be fulfilled in
level 2, and none in level 3. Patients at level 3 have to fulfil at least one of the parameters in level 3 [16].
HbA1c haemoglobin A1c, CVD cardiovascular disease, MACE major cardiovascular event, NYHA the New York Heart Association functional classification in patients
with heart disease [36]
aSevere insulin resistance: Insulin dose > 2.0 U/kg/day
bVery fluctuating plasma glucose: Daily plasma glucose values of > 15 mmol/L or < 5 mmol/L
cPeripheral neuropathy: Vibration perception threshold ≥ 25 mV evaluated by a biothesiometer
dPeripheral artery disease: Ankle-brachial index < 0.9 with or without symptomatic claudication
eMicro-albuminuria: > 1 occasion of urine albumin/creatinine ratio between 30 and 299 mg/g
fMacro-albuminuria: Urine albumin/creatinine ratio ≥ 300 mg/g or an estimated glomerular filtration rate < 45 mL/min
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patients who are either participating in other studies that
potentially may affect the primary outcome of our study,
or patients participating in studies which include blood
sampling amounting to > 5 % of the blood volume in a
2 month period prior to the randomisation and/or the
follow-up visits. The risk stratification level is assessed
by the endocrinologist during the 12- and 24-months
follow-up. If the patient has shifted from level 2 to level
3, the patient is excluded from the study. These patients
will be offered long-term follow-up in the diabetes out-
patient clinic. Patients changing from level 2 to level 1
will continue their participation in the study.
Randomisation
Patients will be randomised to the intervention or con-
trol groups in a 1:1 ratio. The randomisation sequence is
computer generated by a statistician, who is not partici-
pating in the study. A secretary in the outpatient clinic
will handle the script and instructions. The secretary will
prepare sealed envelopes in accordance with instruc-
tions, and the envelopes will be stored and administered
by the secretary during the period of inclusion. There
will be an envelope prepared for each GP, and we will
randomise the patients in blocks of two since we aim at
each GP having an equal number of patients in the
intervention and control group. The randomisation will
be performed immediately after the baseline screening
visit. Healthcare professionals involved in the study, in-
cluding the principal investigator, will be blinded to the
randomisation process. The allocation will be revealed
after the screening visit. Further blinding is not possible
due to the circumstances of the intervention.
Intervention group
Patients in the intervention group will be randomised to
a shared care programme with joint participation in the
delivery of care by the GP and the outpatient clinic. It
comprises four visits a year, namely one annual compre-
hensive check-up at the outpatient clinic and three quar-
terly visits at their GP (Fig. 3). The annual
comprehensive check-up will include biochemical tests,
electrocardiogram, fundus photography, feet examin-
ation including biothesiometry to detect early signs of
peripheral neuropathy, consultations with a diabetes
Screening visit at the outpatient clinic:
• Samples of blood and urine. Electrocardiogram
• Consultation with a diabetes nurse including assessment of 
feet and fundus photography
• Consultation with an endocrinologist including adjustment of 
treatment and risk stratification
• Additional data collection for the project
Randomisation of eligible patients
Shared care / cross sectoral Outpatient clinic / mono 
sectorial
Quarterly consultation with the
general practitioner
Quarterly consultation with an 
endocrinologist
Quarterly consultation with a health 
professional in general practise
Quarterly consultation with an 
endocrinologist
Quarterly consultation with a health 
professional in general practise
Quarterly consultation with an 
endocrinologist
Annual check-up in the 
outpatient clinic
• Samples of blood and urine. 
Electrocardiogram
• Consultation with a diabetes 
nurse including assessment of 
feet and fundus photography 
• Consultation with an 
endocrinologist including 
adjustment of treatment and 
risk stratification
• Additional data collection for the 
project
Annual check-up in the
outpatient clinic
• Samples of blood and urine. 
Electrocardiogram
• Consultation with a diabetes 
nurse including assessment of 
feet and fundus photography 
• Consultation with an 
endocrinologist including 
adjustment of treatment and 
risk stratification
• Additional data collection for 
the project
Fig. 3 Schematic diagram of the intervention
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nurse focusing on life-style intervention and compliance,
and an endocrinologist focusing on an individualised opti-
mal pharmacologic treatment, prevention of complications
and a target-oriented treatment plan for the following year
(Fig. 2). All the procedures will be performed the same day
during a two-to-three hour visit. The first visit at the GP’s
office after the annual comprehensive check-up will be car-
ried out by the GP. The following two visits can be handled
by either the GP or the practice nurse according to stand-
ard procedures at the local primary healthcare clinic. No
further interventions related to the trial will be conducted
in the general practices, as healthcare professionals should
manage the delivery of care as usual. In order to secure
transition of knowledge from the outpatient clinic to the
GP, a copy of the medical record statement will be sent
electronically to the GP after the annual comprehensive
check-up. This report includes a plan and targets for the
T2D treatment on different key parameters such as HbA1c
and blood pressure. Furthermore, we will use a direct elec-
tronic communication system to enable communication
across the interface of the different GPs and the outpatient
clinic. This is a well-established secure communication
channel for exchanging messages, which is available for all
healthcare professionals in both the primary and secondary
healthcare sector in the Capital region of Denmark. In case
of urgent problems or questions, the GPs can call a Dia-
betes Hotline, which can be called every day during work-
ing hours and is answered directly by an endocrinologist in
the outpatient clinic. Patients in the intervention group will
receive a leaflet and verbal information about the free life-
style rehabilitation services offered by their local municipal-
ity. This includes patient education, physical activity,
dietician consultations, and smoking cessation courses. Fur-
thermore, they will be informed that questions concerning
T2D, in the period between the annual comprehensive
check-ups, should be addressed to the health professionals
at the GP’s office.
Control group
Patients in the control group will be attending a well-
established visiting algorithm consisting of four visits
a year with the diabetes team at the outpatient clinic,
namely an annual comprehensive check-up, identical
to the one received by the intervention group, and
three quarterly visits. During the three quarterly
visits, they will be seen by an endocrinologist accord-
ing to the visiting algorithm (Fig. 3). Patients receiv-
ing usual care will be offered lifestyle rehabilitation
services such as patient education, physical activity
and dietician consultations at the hospital. Any ques-
tions or uncertainties concerning their T2D should be
addressed to the healthcare professionals at the out-
patient clinic.
Study data
All study data will be collected in connection with the
annual comprehensive check-up in the outpatient clinic
at the baseline-screening visit, as well as 12, 24 and
36 months after baseline. Data will be obtained from
medical records, laboratory databases, self-reported pa-
tient questionnaires and face-to-face by the primary in-
vestigator who does not take part in the treatment or
care of the patients. All data will be registered in an Epi-
data database [32]. The database is stored at Gentofte
Hospital in a secure purpose-designed password-
protected web-based file system.
The primary outcome is the difference in mean HbA1c
between the two groups measured at 12-, 24- and 36-
months follow-up. The secondary outcome is the pro-
portion of patients who meet the set of Danish standard
indicators reflecting quality of care at 12, 24 and
36 months follow-up [33]. These indicators cover seven
areas, including HbA1c, blood pressure, low density lipo-
protein, albuminuria, fundus photography, foot examin-
ation, smoking status and proper treatment and control
of these factors. The indicators are primarily based on
process variables, but do include a few numerical
variables.
Other outcomes are listed below:
Clinical characteristics: Blood pressure, weight and
body mass index.
Diabetes-related laboratory parameters and character-
istics: C-peptide, insulin, lipids, liver function tests, kid-
ney function tests, electrolytes, coagulation factors,
thyroid-stimulating hormone, cardiovascular biomarkers,
vitamin D, urine albumin/creatinine ratio, and registra-
tion of diabetes-related medication.
Healthcare professionals’ experiences with shared care:
A questionnaire evaluating the experiences of the par-
ticipating GPs and the endocrinologists after the com-
pletion of the 12- and 36-month follow-up periods.
Patient-reported outcomes: Estimation of general qual-
ity of life, diabetes-related symptoms, alcohol consump-
tion patterns as well as patients’ experiences of family
network and function.
The four questionnaires used are:
Short Form 36 (SF-36): SF-36 is a generic self-
administered patient questionnaire measuring quality
of life [34, 35]. The 36 items of SF-36 are grouped
into eight domains: physical function, physical limita-
tions, bodily pain, general health, vitality, social func-
tion, emotional limitation and mental health. The
answers of each scale are transformed into a 0–100
score. An increase in the score indicates less disabil-
ity. The eight domains can be divided into physical
and mental health summary scales, respectively. SF-36
has been validated and is reliable in a range of lan-
guages, including Danish [36].
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Diabetes Symptom Checklist – Revised (DSC-R): DSC-
R is a disease-specific questionnaire measuring the oc-
currence and perceived burden of T2D-symptoms [37].
It comprises 34 items grouped into eight domains:
hyperglycaemic, hypoglycaemic, psychological-cognitive,
psychological-fatigue, cardiovascular, neurological-pain,
neurological-sensory, and ophthalmologic [37, 38]. It is a
self-administered questionnaire. For each item, patients
answer whether or not they have experienced the de-
scribed symptom within the last 4 weeks, and if “yes”,
they specify how troublesome the symptom has been on
a 5-point Likert scale. Each domain is calculated by add-
ing up the scores for each item (range, 1–5 points) and
then divide the summed score by the number of items
within the domain. A reduction in score indicates less
diabetes symptom distress. DSC-R is a previously vali-
dated, reliable measurement instrument, sensitive to
changes over time [38].
The Alcohol Use Disorders Identification Test
(AUDIT): The AUDIT was developed on behalf of the
World Health Organization as a screening tool for iden-
tifying persons with hazardous and harmful alcohol con-
sumption patterns [39, 40]. It consists of 10 questions
divided into three domains: hazardous alcohol use, de-
pendence symptoms and harmful alcohol use. Each
question has three or five response options and each an-
swer triggers a score of 0–4 points. The scores are added
up to a total score ranging from 0 to 40 points. Seven
points is defined as the cut-off representing an alcohol
problem. A higher score indicates a more hazardous and
harmful alcohol consumption pattern [39].
Family assessment measure III (FAM-III): FAM-III is a
self-administered questionnaire assessing family func-
tioning. It consists of three 14-item questionnaires; the
general scale examines the general health of the family;
the dyadic relationship scale assesses how family mem-
bers view their relationship with each other; and in the
self-rating scale, individuals rate their own functioning
within the family. Each item is answered on a 4-point
Likert scale, giving a total score of 0–168. Low scores in-
dicate a strong and well-functioning family, while high
scores indicate a problematic and dysfunctional family.
It is a useful, validated instrument for measuring family
functioning during the course of treatment [41].
Population size calculation
A power calculation was conducted according to criteria
for non-inferiority trials [42, 43], and based on the pri-
mary outcome measure HbA1c at 12-month follow-up.
The non-inferiority margin was set at 0.4 % (1 % is ap-
proximately 11 mmol/mol) based on both clinical judge-
ment and a guideline from the European Medicines
Agency identifying the non-inferiority margin for HbA1c
above 0.3 % (3 mmol/mol) [44]. The standard deviation
of HbA1c was set at 10 mmol/mol, based on a recent
study on patients with risk stratification level 2 attending
our outpatient clinic [31]. With a non-inferiority margin
at HbA1c 4.4 mmol/mol, an alpha of 0.05 and a power at
0.8, as well as an estimated dropout rate of 10 %, the
sample size has been estimated to 140 participants.
Qualitative study data
In the qualitative process analysis of the study the aim is
to explore and explain how the specific programme
works for those involved, rather than focusing on end-
points [45]. Data will be generated by interviews with
patients and family members 1 year after inclusion in
the study. Dyadic interview will examine the interaction
between the participants, and thereby obtain details of
discrepancies and similarities between them [46].
Interviews will initially be guided by a semi-structured
interview guide developed on the basis of knowledge
from earlier studies and the FAM-III questionnaire. The
interview guide will change dynamically according to
theoretical sampling and therefore data collection and
analysis of previous interviews will guide the following
interview in a constant comparative method throughout
the entire research process [47]. Approximately 20 pa-
tients (10 from each arm) and their family members will
be included consistent with theoretical sampling and
hence preliminary inclusion criteria’s are not desirable
nor possible. Further participants can be included if the-
oretical saturation is not achieved [47]. All interviews
will be conducted at the patient’s home or at the hospital
according to the patient and the family member’s wish.
Participants will be excluded if they for any reason are
not able to manage a 45–60 minute interview.
Statistical analysis
We will present and compare the baseline demographics
as well as clinical and diabetes-related characteristics of
the intervention and the control group. The statistical
comparison will be conducted on the basis of t tests or
analysis of variance as appropriate for comparing means
and χ2 tests for categorical or binary data. The primary
outcome will be tested by constructing a 90 % two-sided
confidence interval for the difference of the means of
HbA1c between the intervention and the control group.
We use the lower bound to determine non-inferiority.
Other outcomes will be tested with superiority analyses
such as linear or logistic regression analysis. For ob-
served differences we will consider a P value less than
0.05 as statistically significant.
Qualitative data analysis
The interviews will be audio-taped for verbatim tran-
scription. The transcripts will be analysed according to
the principles of grounded theory [47, 48] to identify
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concepts, core categories and patterns. The computer
software program NVivo10 will be used to support orga-
nising data [49]. With a main focus on “what is going on
in the data” tentative links between categories will
emerge and pattern out theoretical connections, consti-
tute the core category, and further theory building. In
order to increase validity, all steps during analysis will be
discussed with researchers experienced in grounded the-
ory. Finally, all authors will determine whether findings
have fit, work, and are relevant and modifiable [47].
Discussion
The overall objective of this study is to evaluate whether
sharing general and specialised healthcare is comparable to
the specialised care delivered in a hospital-based outpatient
setting for patients with T2D who are at intermediate risk
of or are already having incipient diabetic complications.
The hypothesis is that the changes in HbA1c at 12-, 24- and
36-month follow-up are comparable between the interven-
tion and the control group. According to previous studies
the evidence for shared care in different chronic diseases,
including T2D, is not clear [20]. Testing new shared care
models as a way of alternative organisation of care for pa-
tients with T2D is therefore important. The majority of
studies on shared care for patients with T2D have been
conducted 15–20 years ago. However, the increasing num-
ber of patients with T2D who are referred to the outpatient
clinics as well as the development and improvements of
electronic systems, clinical databases and communication
channels during the last decades has made it highly
relevant to test shared care models in new settings.
Shared databases and electronic correspondence
across the interface of the primary and secondary
healthcare sectors are expected to blur the boundaries
between the different healthcare sectors.
If shared care is shown to be effective, it can provide new
ways of organising care for the globally increasing number
of patients with T2D, allowing more patients to benefit
from the specialised diabetes team at outpatient clinics
while keeping a close contact with the GP, who often has a
broader knowledge of the individual. A well-structured clin-
ical follow-up and treatment, supported by the diabetes
team, can potentially improve the long-term prognoses for
patients who are at intermediate risk of or already having
incipient diabetic complications. The Steno-2 study
showed that intensified focus on lifestyle and multi-
pharmacological treatment of patients with T2D and
microalbuminuria reduced the development of micro- and
macrovascular complications significantly at 13.3 years
follow-up compared to patients receiving conventional
therapy by the GP [13]. Preventing or delaying the onset
of complications for patients with T2D is essential, as the
development of these complications significantly increase
socioeconomic costs and can cause personal disabilities.
Thus, it is well known that, as the patient moves from a
state corresponding to a risk stratification level 2 to level 3,
it is associated with multiple increases in direct and indirect
cost to the healthcare sector and the community [11, 12].
Multiple parameters are known to have a significant
effect on outcome. Apart from testing the primary out-
come, HbA1c, we plan to investigate factors such as
quality of life, blood pressure, lipid levels, family func-
tion and other clinical characteristics in order to test any
negative or positive impact of shared care in accordance
with previous studies showing a prognostic impact of
these factors, e.g. blood pressure [50] and family net-
work and functionality [51, 52].
The strength of our study is that it is designed as a rando-
mised controlled trial. The majority of previous studies,
which have tested shared care models for patients with
chronic diseases, have been with limited robustness in
study designs in terms of testing multifaceted interventions,
limited periods of follow-up and not meeting the quality
criteria of Cochrane Review Group for randomised con-
trolled trials [20]. Furthermore, the qualitative process
evaluation can provide knowledge about the appropriate-
ness of disseminating a particular intervention to other
relevant sites and about which elements to improve and
which to keep [53].
Since the study is conducted in a Danish setting, the re-
sults may not be generalised to healthcare settings in other
countries. However, we believe that the results may inspire
healthcare planners in other countries, as the organisation
of the Danish healthcare system in a primary and secondary
healthcare sector is comparable to the organisation of
healthcare in a range of other countries in Europe and
elsewhere.
Other limitations must also be considered. A potential
bias in the study is that we recruit GPs who have shown
interest in the project, and therefore may not be representa-
tive for the whole population of GPs. It could therefore be
either GPs who have a special interest and knowledge about
T2D or GPs who want to learn and become more
knowledgeable about T2D. However, the substantial num-
ber of different GPs in the present trial may result in vari-
ability in the GPs interest in and knowledge about T2D.
We aim to include approximately six patients from each
GP, avoiding a given GP from including significantly more
patients than the others.
If the findings of this study support future implementa-
tion of a shared care model for patients with T2D, more pa-
tients could benefit of the specialised diabetes team, but
with fewer patients followed solely on a routine basis in the
outpatient clinic, thus potentially increasing cost–benefit
relationships. Both patients and the GPs may benefit from
tight and improved collaboration with the diabetes team.
The trial may therefore impact future organisation of dia-
betes care.
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Trial status
The trial is ongoing. The recruitment of patients started
August 2015 and is expected to be completed by De-
cember 2016.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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